Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: A prospective, single-institute study

(2014) Masakuni Serizawa et al.   CANCER

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

(2014) Mark G. Kris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers

(2014) Anya M. Litvak et al.   Journal of Thoracic Oncology

BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib

(2014) Sara D. Robinson et al.   LUNG CANCER

BRAF-mutations in non-small cell lung cancer

(2014) Odd Terje Brustugun et al.   LUNG CANCER

BRAF Mutations in Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

(2014) Dong Chen et al.   PLoS One

Prognostic Value Analysis of Mutational and Clinicopathological Factors in Non-Small Cell Lung Cancer

(2014) Chenguang Li et al.   PLoS One

Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma

(2014) haichuan hu et al.   OncoTargets and Therapy

Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non-Small Cell Lung Cancer

(2013) S. Cardarella et al.   CLINICAL CANCER RESEARCH

HER2 and lung cancer

(2013) Lorenza Landi et al.   Expert Review of Anticancer Therapy

Dramatic Response Induced by Vemurafenib in aBRAFV600E-Mutated Lung Adenocarcinoma

(2013) Solange Peters et al.   JOURNAL OF CLINICAL ONCOLOGY

Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

(2013) Julien Mazières et al.   JOURNAL OF CLINICAL ONCOLOGY

Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas

(2012) M. E. Arcila et al.   CLINICAL CANCER RESEARCH

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu

(2012) J. De Grève et al.   LUNG CANCER

Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status

(2012) She-Juan An et al.   PLoS One

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations

(2011) Antonio Marchetti et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers

(2011) Kenji Tomizawa et al.   LUNG CANCER

Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers

(2011) Chenguang Li et al.   PLoS One

East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians

(2011) Wei Zhou et al.   Chinese Journal of Cancer

Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases

(2010) Yihua Sun et al.   JOURNAL OF CLINICAL ONCOLOGY

HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy

(2009) S. A. Perera et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA